Empagliflozin Alleviates Atherosclerosis Progression by Inhibiting Inflammation and Sympathetic Activity in a Normoglycemic Mouse Model

BACKGROUND: Recent clinical studies have revealed that sodium glucose co-transporter 2 inhibitors (SGLT2i) reduced cardiovascular events in type 2 diabetes. Here, we investigated whether empagliflozin, as a kind of SGLT2i, could alleviate atherosclerosis progression in non-diabetic mice. METHODS: Ap...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yihai, Wu, Mingyue, Xu, Biao, Kang, Lina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8180283/
https://www.ncbi.nlm.nih.gov/pubmed/34103961
http://dx.doi.org/10.2147/JIR.S309427

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8180283/
https://www.ncbi.nlm.nih.gov/pubmed/34103961
http://dx.doi.org/10.2147/JIR.S309427

Ejemplares similares